Cann reissued their buy rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a report issued on Tuesday. The brokerage currently has a $199.00 price objective on the biopharmaceutical company’s stock.

“Total Q3 revenue of $142.8 million included a $100 million upfront payment. Net of the upfront payment, revenue was 27.4% higher than our estimated $33.6 million due to stronger than estimated Zejula sales. Total operating expenses of $164.9 million were 3.0% lower than our estimated $170.0 million due to lower than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56.”,” Cann’s analyst commented.

Several other equities research analysts have also recently weighed in on the stock. Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the company a buy rating in a research report on Wednesday, July 19th. ValuEngine cut shares of TESARO from a hold rating to a sell rating in a research report on Monday, July 17th. BidaskClub cut shares of TESARO from a sell rating to a strong sell rating in a research report on Wednesday, July 19th. Citigroup Inc. reissued a buy rating and set a $216.00 price target on shares of TESARO in a research report on Monday, September 11th. Finally, Zacks Investment Research cut shares of TESARO from a hold rating to a sell rating in a research report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. TESARO currently has an average rating of Hold and a consensus target price of $164.85.

Shares of TESARO (NASDAQ TSRO) opened at $91.09 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 5.41. TESARO has a 12-month low of $89.00 and a 12-month high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm’s revenue for the quarter was up 740.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.72) EPS. sell-side analysts forecast that TESARO will post -8.21 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cann Reiterates “Buy” Rating for TESARO, Inc. (TSRO)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/cann-reiterates-buy-rating-for-tesaro-inc-tsro/1695912.html.

In other TESARO news, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,692 shares of company stock valued at $4,628,976. 40.50% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in TESARO by 5.7% during the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after purchasing an additional 195,590 shares in the last quarter. Vanguard Group Inc. increased its stake in TESARO by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after purchasing an additional 62,104 shares in the last quarter. State Street Corp increased its stake in TESARO by 17.9% during the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after purchasing an additional 177,057 shares in the last quarter. BB Biotech AG increased its stake in TESARO by 6.5% during the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after purchasing an additional 53,408 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in TESARO during the 2nd quarter valued at about $100,301,000.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.